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Lysophosphatidate (LPA) mediates multiple cellular re-
sponses via heterotrimeric G protein coupled LPA-1,
LPA-2, and LPA-3 receptors. Many G protein-coupled re-
ceptors stimulate ERK following tyrosine phosphoryla-
tion of growth factor receptors; however, the mecha-
nism(s) of transactivation of receptor tyrosine kinases are
not well defined. Here, we provide evidence for the in-
volvement of phospholipase D (PLD) in LPA-mediated
transactivation of platelet-derived growth factor recep-
tor- (PDGF-R). In primary cultures of human bronchial
epithelial cells (HBEpCs), LPA stimulated tyrosine phos-
phorylation of PDGF-R and threonine/tyrosine phospho-
rylation of ERK1/2. The LPA-mediated activation of ERK
and tyrosine phosphorylation of PDGF-R was attenu-
ated by tyrphostin AG 1296, an inhibitor of PDGF-R ki-
nase, suggesting transactivation of PDGF-R by LPA. Fur-
thermore, LPA-, but not PDGF -chain homodimer-
induced tyrosine phosphorylation of PDGF-R was
partially blocked by pertussis toxin, indicating coupling
of LPA-R(s) to Gi. Exposure of HBEpCs to LPA activated
PLD. Butan-1-ol, which acts as an acceptor of phosphati-
date generated by the PLD pathway, blocked LPA-medi-
ated transactivation of PDGF-R. This effect was not seen
with butan-3-ol, suggesting PLD involvement. The role of
PLD1 and PLD2 in the PDGF-R transactivation by LPA
was investigated by infection of cells with adenoviral con-
structs of wild type and catalytically inactive mutants of
PLD. LPA activated both PLD1 and PLD2 in HBEpCs;
however, infection of cells with cDNA for wild type PLD2,
but not PLD1, increased the tyrosine phosphorylation of
PDGF-R in response to LPA. Also, the LPA-mediated
tyrosine phosphorylation of PDGF-R was attenuated by
the catalytically inactive mutant mPLD2-K758R. Infec-
tion of HBEpCs with adenoviral constructs of wild type
hPLD1, mPLD2, and the inactive mutants of hPLD1 and
mPLD2 resulted in association of PLD2 wild type and
inactive mutant proteins with the PDGF-R compared
with PLD1. These results show for the first time that
transactivation of PDGF-R by LPA in HBEpCs is regu-
lated by PLD2.
Lysophosphatidate (LPA)1 is a potent bioactive lipid that is
implicated in cell proliferation, differentiation, suppression of
apoptosis, tumor metastasis, and cytoskeletal reorganization
(1–5). In plasma, LPA is present at 0.2 M, but activated
platelets produce high amounts of LPA which can reach 1–10
M, making it the most abundant mitogen/survival factor pres-
ent in serum (6). Mammalian cells contain small quantities of
intracellular LPA; however, many biological actions of LPA are
mediated by specific G protein-coupled receptors (GPCRs),
LPA-1, LPA-2, and LPA-3 (formerly called EDG-2, -4, and -7).
LPA, akin to sphingosine 1-phosphate (S1P), binds with high
affinity to its receptors that are coupled to multiple types of
heterotrimeric G proteins (Gi, Gq, and G12/13). Ligation of LPA
to LPA-Rs (LPA-Rs) leads to a myriad of signal transduction
pathways including release of [Ca2]i, activation of protein
kinase C, phosphatidylinositol-3-kinase, mitogen-activated
protein kinases (ERK1 and ERK2), tyrosine kinases, and phos-
pholipases (7). LPA-induced release of [Ca2]i and decreased
cAMP are pertussis toxin (PTx)-sensitive, suggesting involve-
ment of Gi (8). LPA-mediated activation of ERK1/2 requires
p21 Ras (9) and is dependent on phosphatidylinositol 3-kinase
signaling through Gi (10). Furthermore, LPA activated the
nonreceptor tyrosine kinase, Src, and Pyk2 (11, 12). LPA-in-
duced Rho activation through G12/13 results in stress fibers,
assembly of focal adhesion, and nuclear factor-B-dependent
gene transcription (13).
LPA activates PLD in various mammalian cells, including
fibroblasts, smooth muscle cells, and prostate cancer cells (14–
16). PLD isoenzymes, PLD1 and PLD2, hydrolyze phosphati-
dylcholine to generate phosphatidate (PA), and they are acti-
vated by hormones, growth factors, neurotransmitters,
cytokines, and reactive oxygen species (17). The second mes-
senger functions of PA are mediated directly or after its con-
version to either diacylglycerol or LPA by the action of PA
phosphohydrolase or phospholipase A1/A2, respectively. PA
derived through PLD regulates protein tyrosine phosphatases,
ERK1/2 phosphorylation, phosphatidylinositol 4-kinase, phos-
phatidylinositol 3-kinase, phosphatidylinositol 4-phosphate
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5-kinase, phagocytic NADPH oxidase, actin polymerization,
coatomer assembly, vesicle trafficking, and cytokine secretion
(18–21). However, the relationships between PLD1 and PLD2
activation and cellular responses have not been well studied.
In contrast to LPARs, the protein growth factor receptors are
receptor tyrosine kinases, and their activation stimulates sig-
naling pathways, involving ERK, phosphatidylinositol 3-ki-
nase, protein kinase C, and phospholipases (1, 22, 23). Recep-
tors for LPA/S1P and growth factors (EGF and PDGF) are
coexpressed in many cell types including endothelial, smooth
muscle, and epithelial cells (24–26). It is now becoming clearer
that cross-talk among lipid mediators, cytokines, and growth
factors regulates the amplitude and specificity of cellular re-
sponses such as secretion, proliferation, and differentiation.
For instance, several agonists of GPCR, such as thrombin,
angiotensin II, bradykinin, S1P, and LPA, not only induce
tyrosine phosphorylation of intracellular signaling proteins,
but also transactivate the growth factor receptors, EGF and
PDGF (27–33). This transactivation amplifies mitogenic sig-
nals from a variety of stimuli. However, relatively little is
known regarding the role and regulation of LPA-mediated
transactivation of PDGF-Rs in mammalian cells.
In the present study, we investigated potential signaling
pathways activated by LPA which regulate the transactivation
of PDGF-R in human bronchial epithelial cells (HBEpCs).
LPA-induced phosphorylation of PDGF-R in HBEpCs was
sensitive to PTx. LPA also stimulated both PLD1 and PLD2 in
HBEpCs; however, PLD2 but not PLD1 activation regulated
LPA-mediated transactivation of PDGF-R. Furthermore,
overexpression of wild type and catalytically inactive mutant of
mPLD2 compared with hPLD1 preferentially formed a complex
with PDGF-R in HBEpCs. Our results show for the first time
that generation of PA by PLD2 activation is involved in LPA-




LPA was obtained from BIOMOL Research Labs (Plymouth, PA).
12-O-Tetradecanoylphorbol-13-acetate, bovine serum albumin (fraction
V), butan-1-ol, butan-3-ol, and dimethyl sulfoxide were purchased from
Sigma. Recombinant PDGF-BB, tryphostins AG 1296 and PTx were
obtained from Calbiochem. PBt and monooleoyl LPA were purchased
from Avanti Polar Lipid Corp (Alabaster, GA). 32Pi (carrier-free) was
obtained from PerkinElmer Life Sciences. RedTaq DNA polymerase
was purchased from Sigma. A cDNA synthesis kit was purchased from
Invitrogen, and a total RNA isolation kit was obtained from Qiagen
(Valencia, CA). Polyclonal antibody against phospho-ERK was obtained
from Cell Signaling (Beverly, MA). Antibodies for total PDGF-R and
phospho-PDGF-R (Tyr-716) were purchased from Upstate Biotechnol-
ogy (Lake Placid, NY), and antibodies against total ERK were from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Phosphatidylcholine-
specific PLD1, human N-terminal, and internal as well as PLD2, mouse
internal, and N-terminal polyclonal antibodies were purchased from
BIOSOURCE International (Camarillo, CA). BEBM and supplement
kit were purchased from BioWhittaker (Walkersville, Frederick, MD).
Primary HBEpCs, passage 2, were procured from Clonetics (San Diego,
CA).
Cell Culture
Primary HBEpCs were cultured in BEBM serum-free medium con-
taining all of the growth factors supplied by Clonetics (BEGM) at 37 °C
in 5% CO2 and 95% air. Cells were grown in to 90% confluence in
T-75-cm2 vented flasks and subsequently propagated in 35-mm dishes.
Cells were grown for 48 h without changing the medium before stimu-
lation with LPA or PDGF-BB in conditioned BEBM (medium collected
from cells cultured for 48 h) containing 0.1% BSA. All experiments were
carried out between passages 2 and 5.
Transfection and Viral Infection
For transient transfection, HBEpCs grown in 6-well plates (60
confluence), were transfected with PDGF-R or PLD2 plasmids (1 g of
cDNA was mixed with 6 l of FuGENE 6/well in 1 ml of BEGM)
according to the manufacturer’s recommendations. After 5 h, the trans-
fection medium was aspirated and 2 ml of regular BEGM was added,
and cells were incubated for 24–48 h. Infection of HBEpCs (60%
confluence) in 35-mm dishes was carried out with purified hPLD1 and
mPLD2 adenoviral particles (50 pfu/cell) in 1 ml of BEGM for 24 h, and
the virus-containing medium was replaced with complete BEGM for
different time periods. For coimmunoprecipitation experiments, cells
were infected with PLD1 or PLD2 adenoviral particles (50 pfu/cell) for
3 h and then transfected with PDGF-R cDNA for 4 h. After transfec-
tion, the medium was removed, conditioned medium was added, and
cells were grown overnight before challenging with LPA or PDGF-BB.
Oligonucleotides for RT-PCR Analysis
LPA Receptors—Total RNA was isolated from HBEpCs using an
RNEasy kit (Qiagen). cDNA was generated using a cDNA synthesis kit
according to manufacturer’s recommendation and subjected to PCR at
94 °C for 2 min following 30 cycles of 94 °C for 1 min, 55 °C for 2 min,
and 72 °C for 3 min, followed by 72 °C for 10 min. The following
oligonucleotide primers were used for RT-PCR analysis of LPA-Rs.
For LPA-1R: forward, 5-GTAATGGTGGTTCTCTATGCTCAC-3; re-
verse 5-GGACAGCACACGTCTAGAAG-3.
For LPA-2R: forward, 5-GTCGAGCCTGCTTGTCTTC-3; reverse,
5-CCAGAGCAGTACCACCTG-3.
For LPA-3R: forward, 5-GGAATTGCCTCTGCAACATCT-3; re-
verse, 5-GAGTAGATGATGGGGTTCA-3.
For -actin: forward, 5-GACTACCTCATGAAGATC-3; reverse,
5-GATCCACATCTGCTGGAA-3.
The PCR products were separated by electrophoresis, and primers
used in these reactions yielded PCR products of 197, 205, 382, and 513
bp, respectively.
PLD1 and PLD2—PCRs were performed for 30 cycles at 94 °C for 2
min followed by denaturation at 94 °C for 1 min, annealing at 60 °C for
2 min, and elongation at 72 °C for 3 min. The following oligonucleotides
primers were used for RT-PCR.
PLD1: forward, 5-TGGGCTCACCATGAGAA-3; reverse, 5-GTCA-
TGCCAGGGCATCCGGGG-3.
PLD 2: forward, 5-TCCATCCAGGCCATTCTGCAC-3; reverse,
5-CGTTGCTCTCAGCCATGTCTTG-3.
PCR products were analyzed by agarose gel electrophoresis, and the
primers used in these reactions yielded products of 642 bp/PLD1a, 528
bp/PLD1b, and 468 bp/PLD2.
Preparation of Cell Lysates, Immunoprecipitation,
and Western Blotting
HBEpCs grown on 60- or 100-mm dishes (90% confluence) were
stimulated with LPA or PDGF-BB, rinsed three times with ice-cold
phosphate-buffered saline containing 1 mM orthovanadate and lysed in
RIPA buffer (20 mM Tris-HCl, pH 7.4, 1% Triton X-100 (v/v), 150 mM
NaCl, 5 mM EDTA, 100 mM NaF, and 1 mM Na3VO4). Cell lysates were
sonicated (3  15 s) on ice, centrifuged at 5,000  g for 5 min at 4 °C,
and protein concentrations were determined with BCA protein assay
kit (Pierce Chemical Co.) using BSA as standard. Equal amounts of
protein (300–500 g) were precleared with 20 l of protein A/G-agarose
for 30 min at 4 °C, centrifuged at 5,000  g for 10 min, supernatants
were incubated with 2 g/ml anti-PDGF-R antibody overnight at 4 °C
followed by the addition of 40 l of protein A/G-agarose and additional
incubation for 2 h at 4 °C. The cell lysates were centrifuged at 5,000 
g for 5 min, washed three times with ice-cold phosphate-buffered saline
containing 1 mM orthovanadate, protein-agarose complexes were disso-
ciated by boiling for 5 min in 2 Lammeli buffer, and samples were
centrifuged in a microfuge at 5,000  g for 5 min. The supernatants
were subjected to SDS-PAGE on 10% gels, transferred to polyvinylidene
difluoride membranes, blocked with 5% (w/v) non-fat dry milk in TBST
(25 mM Tris, pH 7.4, 137 mM NaCl, and 0.1% Tween 20) for 1 h and
incubated with primary antibodies against PDGF-R or phospho-
PDGF-R (1:1,000 dilution) in TBST overnight at 4 °C. The membranes
were washed three times with TBST at 30-min intervals and then
incubated with either mouse or rabbit horseradish peroxidase-conju-
gated secondary antibody (1:3,000 dilution) for 2–4 h at room temper-
ature. The membranes were developed with the enhanced chemilumi-
nescence detection system according to manufacturer’s instruction, and
blots were quantified by densitometry and image analysis with Molec-
ular Analyst software. Changes in PDGF-R phosphorylation were
expressed as -fold change normalized to total cellular PDGF-R protein.
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Measurement of Phospholipase D in Intact Cells
HBEpCs in 35-mm dishes were labeled with 30 Ci/ml 32Pi BMGM
for 18–24 h at 37 °C in 5% CO2 and 95% air incubator. Cells were
pretreated with vehicle alone or specific agents for specified times prior
to challenge with LPA. Cells were then challenged with LPA in vehicle
containing 0.1% BSA or other agents and in the presence of 0.05%
butan-1-ol. In some experiments, incubations were also carried out in
the presence of 0.05% butan-3-ol that served as additional controls.
Incubations were terminated by the addition of 1 ml of methanol:HCl
(100:1 v/v), cells were scraped into glass tubes, and lipids were ex-
tracted by the addition of 1 ml of methanol:HCl (100:1 v/v), 2 ml of
chloroform, and 0.8 ml of 1 M HCl (21). Formation of [32P]PBt, as a
result of PLD activation and transphosphatidylation of [32P]PA, to
butan-1-ol but not butan-3-ol, was separated from the total lipid extract
by thin layer chromatography on 1% potassium oxalate plates with the
upper phase of ethyl acetate:2,2,4-trimethyl pentane:glacial acetic acid:
water (65:10:15:50 v/v) as the developing solvent system. Unlabeled PBt
was added as carrier during separation of labeled lipids that were
visualized by exposure to iodine vapor. Radioactivity associated with
PBt was counted by liquid scintillation counting, and all values were
normalized to 106 dpm in total lipid extract. [32P]PBt formed in control
and agonist challenged samples was expressed as dpm/dish or percent
control.
Statistical Analysis
Data are expressed as means of triplicates  S.D. from at least three
independent experiments. All results were subjected to statistical anal-
ysis using one-way analysis of variance.
RESULTS
Expression of LPA-Rs in HBEpCs—Recent cloning of GPCRs
for LPA has identified three high affinity receptors, namely
LPA-1, LPA-2, and LPA-3 in mammalian cells and tissues. In
the lung and human airway smooth muscle cells, mRNA for all
three LPA-Rs has been shown by RT-PCR (46). However, the
relative expression and functional role of LPA-Rs in airway
cells are unknown. Therefore, we determined the mRNA and
protein expression of LPA-R subtypes in primary cultures of
HBEpCs using RT-PCR, Western blotting, and immunocyto-
chemistry. As shown in Fig. 1A, mRNA for all the three LPA-Rs
was identified in HBEpCs. The presence of LPA-1 (50 kDa),
LPA-2 (45 kDa), and LPA-3 (40 kDa) receptor proteins was also
confirmed by Western blotting with specific antibodies to the
three receptor proteins in HBEpCs (Fig. 1B) (provided by Glaxo
Smith Kline, King of Prussia, PA). Furthermore, the Western
blot results were complemented by immunocytochemical local-
ization using LPA-R antibodies. All three LPA-Rs were also
detected in HBEpCs by immunocytochemistry (Fig. 1C). LPA-3
was barely detectable compared with LPA-1 and LPA-2 by
immunofluorescent microscopy. Both LPA-1 and LPA-2 were
not only localized at the plasma membrane, but were also
distributed in the cytoplasm of the cell. The distribution of
LPA-1 appeared punctated and located in the perinuclear
membrane. The staining of LPA-3 was more pronounced at the
perinuclear membrane compared with the plasma membrane
or cytoplasm distribution. These results indicate that LPA-Rs
are not only present at the plasma membrane, but also distrib-
uted in the cytoplasm and perinuclear membranes.
LPA-induced ERK1/2 Activation Is Sensitive to AG 1296 and
PTx in HBEpCs—Previous studies have demonstrated stimu-
lation of mitogenic signaling pathways for S1P, LPA, and
growth factors in human airway smooth muscle and epithelial
cells (1, 21, 34, 35). To examine ERK activation further,
HBEpCs were challenged with 1 M LPA or 20 ng/ml PDGF-
BB, and phosphorylation of ERK was analyzed by Western
blotting with phospho-specific antibodies against threonine/
tyrosine residues. As shown in Fig. 2, LPA and PDGF stimu-
lated ERK1/2 phosphorylation by 2.2- and 1.8-fold, respec-
tively. Enhanced phosphorylation of ERK, normalized to total
ERK, was detected as early as 2 min of exposure to either LPA
or PDFG-BB, whereas maximum phosphorylation ( 3–4-fold)
occurred at 15 min and declined thereafter (results not shown).
As LPA and PDGF stimulated ERK, we next investigated the
mechanisms of ERK activation. Treatment of cells with
PD98059, a known inhibitor of mitogen-activated protein ki-
nase/ERK kinase, blocked ( 95%) both LPA- and PDGF-BB-
mediated phosphorylation (results not shown). These results
suggest that LPA- and PDGF-BB-induced activation of ERK is
coupled to mitogen-activated protein kinase/ERK kinase sig-
naling in HBEpCs. Pretreatment of cells with the PDGF-R-
selective tyrosine kinase inhibitor tyrphostin AG 1296 com-
pletely blocked PDGF-BB-stimulated ERK phosphorylation,
whereas LPA activation of ERK was only partially blocked.
This suggests that PDGF-R kinase activity is required for part
of the LPA activation of the ERK cascade (Fig. 2). Previous
studies showed that in Beas-2B cells, S1P-induced activation of
ERK was sensitive to PTx (21), indicating the involvement of
Gi-coupled S1P receptors. In HBEpCs pretreated with 100
ng/ml PTx for 3 h, the LPA-stimulated ERK1/2 phosphoryla-
tion was attenuated by about 95% (Fig. 3). These results dem-
onstrate that LPA-Rs are coupled to PTx-sensitive Gi in the
ERK signaling cascade.
LPA Induction of PDGF-R Phosphorylation Is Coupled
through Gi—The inhibition of LPA-induced ERK activation by
AG 1296 suggests that LPA-R stimulation results in PDGF-R
transactivation. Therefore, we assessed PDGF-R phosphoryl-
ation in response to LPA. HBEpCs were challenged with LPA,
and PDGF-R phosphorylation was studied by Western blot-
ting with phospho-specific PDGF-R antibody (specific for ty-
rosine 716). As shown in Fig. 4, stimulation of HBEpCs with
varying concentrations of LPA (0.1–5 M) increased PDGF-R
tyrosine phosphorylation. Enhanced phosphorylation of
FIG. 1. Detection of LPA-Rs by RT-PCR, Western blotting, and
immunocytochemistry. A, total RNA was extracted from primary
HBEpCs, and transcription of the genes encoding LPA-Rs (1, 2, and 3)
was assessed by RT-PCR ( indicates in the absence of RNA, and 
indicates in the presence of 2 g of RNA) with primers to the indicated
receptors and -actin. RT-PCR products were visualized by ethidium
bromide staining after separation on agarose gels. B, cell lysates (30 g
of protein) were subjected to SDS-PAGE and analyzed by Western
blotting with LPA-1, LPA-2, or LPA-3 receptors. Each Western blot is
representative of three independent experiments. C, HBEpCs grown on
coverslips to 90% confluence were subjected to immunostaining
with LPA-R antibodies and examined by fluorescent microscopy.
Each immunofluorescence image is representative of three separate
experiments.
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PDGF-R after 15 min of exposure to 0.1 M LPA (4-fold
increase over control) increased to 7-fold with 0.5 M LPA
(Fig. 4). Furthermore, LPA stimulated PDGF-R phosphoryla-
tion in a time-dependent manner (Fig. 5). Enhanced tyrosine
phosphorylation of PDGF-R (2-fold) was detected within 2
min of challenge to LPA, whereas maximum phosphorylation
(10-fold) was observed at 5 min and declined thereafter up to
30 min (Fig. 5). In addition to tyrosine 716, PDGF-R is also
tyrosine phosphorylated at other sites by PDGF. We therefore
compared the Western blots of phospho-specific tyrosine 716
antibodies with immunoprecipitation of PDGF-R and West-
ern blotting with anti-phosphotyrosine antibody. HBEpCs were
transfected with PDGF-R wild type plasmid for 18 h, and cells
were stimulated with 1 M LPA for different times. Cells ly-
sates (1.0 mg of protein) were immunoprecipitated with
PDGF-R antibody, and precipitates were analyzed by Western
blotting with anti-phosphotyrosine antibody. As shown in Fig.
5, overexpression of cells with wild type PDGF-R plasmid and
stimulation with LPA provided a similar time-dependent tyro-
sine phosphorylation of PDGF-R. Phosphorylation of
PDGF-R was detected after 5 min of exposure to 100 nM LPA
( 3-fold increase over control), which increased to  7-fold
with 500 nM LPA and plateaued at higher concentrations of
LPA (1 and 5 M). These results clearly demonstrate phospho-
rylation of PDGF-R by LPA in HBEpCs.
To ascertain further the role of LPA-R stimulation by LPA in
transactivation of PDGF-R, we investigated the effect of tyr-
phostin AG 1296 on tyrosine phosphorylation of PDGF-R. The
LPA-induced tyrosine phosphorylation of PDGF-R (6-fold
increase over control in 10 min) was attenuated by tyrphostin
AG 1296 in a dose-dependent manner with a 50% inhibition
at 1 M AG 1296 (Fig. 6A). However, the basal phosphorylation
FIG. 3. PTx blocks LPA-induced ERK phosphorylation.
HBEpCs (passage 2,  90% confluence in 35-mm dishes) were pre-
treated with 100 ng/ml PTx for 3 h. Cells were challenged with 1 M
LPA for 15 min, then cell lysates were subjected to SDS-PAGE and
Western blotted with phospho-specific and pan-ERK antibodies. Values
are the means  S.D. of three independent experiments in triplicate.
-Fold changes in ERK phosphorylation were normalized to total ERK. *,
p  0.05 compared with vehicle control; **, p  0.05 compared with
vehicle control; ***, p  0.05 compared with LPA treatment.
FIG. 2. Effect of tyrphostin AG 1296 on LPA- and PDGF-BB-mediated ERK phosphorylation. HBEpCs (passage 2,  90% confluence in
35-mm dishes) were pretreated with BEBM or BEBM plus 5 M AG 1296 for 1 h and then stimulated with 1 M LPA (A) or 20 ng/ml PDGF-BB
(B) for 15 min. Cell lysates (30 g of protein) from A and B were subjected to SDS-PAGE and Western blotted with phospho-specific and pan-ERK
antibodies. Values are the means  S.D. from three independent experiments in triplicate, and -fold changes in ERK phosphorylation were
normalized to total ERK. The histograms are shrunk horizontally to fit under the blots. *, p  0.05 compared with vehicle control; **, p  0.05
compared with LPA or PDGF-BB treatment.
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of PDGF-R, in the absence of LPA, was not drastically altered
by AG 1296 (Fig. 6A). As expected, pretreatment of cells with 1
M AG 1296 for 1 h also abolished the PDGF-BB (20 ng/ml)-
mediated PDGF-R phosphorylation (Fig. 6B). These results
provide further evidence that LPA causes activation of the
PDGF-R in HBEpCs.
LPA-Rs are coupled to a variety of heterotrimeric G proteins
(7). Previously, we and others showed that Gi coupling played
an important role in S1P- and LPA-mediated signal transduc-
tion in Beas-2B cells (21) and fibroblasts (36). To determine the
contribution of Gi in LPA-induced PDGF-R transactivation,
HBEpCs were pretreated with 100 ng/ml PTx for 12 h prior to
stimulation with 1 M LPA for 15 min. This treatment dramat-
ically inhibited tyrosine phosphorylation of PDGF-R (70%
inhibition compared with stimulation by LPA alone), whereas
PTx had no effect on basal phosphorylation of PDGF-R (Fig. 7).
As a control, we established that PTx had no significant effect
on PDGF-BB-mediated tyrosine phosphorylation of PDGF-R
(results not shown). These results suggest that LPA-induced
transactivation of PDGF-R is partly regulated by coupling of
an LPA-R to Gi.
Role of PLD in LPA-induced PDGF-R Transactivation—
The internalization of growth factor receptors in response to
EGF or PDGF involves endocytosis (37, 38). Because PLD has
been implicated in protein trafficking and membrane fusion,
we hypothesized that LPA-mediated PLD stimulation and PA
generation may be involved in PDGF-R transactivation in
HBEpCs. RT-PCR revealed the presence of mRNA for PLD1
and PLD2, whereas Western blotting with specific antibodies
confirmed the expression of PLD1 (116 kDa) and PLD2 (100
kDa) proteins in primary cultures of HBEpCs (Fig. 8). As
shown in Table I, exposure of 32P-labeled HBEpCs to 1 M LPA
for 10 min, in the presence of 0.05% butan-1-ol, significantly
enhanced [32P]PBt accumulation, an index of PLD activation
(39). However, under similar incubation condition, 50 ng/ml
PDGF-BB did not enhance [32P]PBt formation (Table I). Fur-
thermore, the PDGF-R kinase inhibitor AG 1296 had no sig-
nificant effect on LPA- or 12-O-tetradecanoylphorbol-13-ace-
tate-induced [32P]PBt formation (Table I). These results
demonstrate that activation of PLD by LPA is not mediated
through PDGF-R in HBEpCs.
The role of LPA-induced PLD activation in transactivation of
the PDGF-R was investigated by using the ability of primary,
but not secondary or tertiary, alcohols to divert PA formation to
accumulation of phosphatidylalcohol. HBEpCs were stimu-
lated with 1 M LPA for 15 min in the absence or presence of
0.1% butan-1-ol or butan-3-ol. As shown in Fig. 9, butan-1-ol,
but not butan-3-ol, blocked LPA-induced PDGF-R phospho-
rylation (LPA,  5-fold increase compared with vehicle; butan-
1-ol plus LPA,  3-fold change) without affecting the basal
phospho-PDGF-R levels. These results demonstrate the in-
volvement of PLD in LPA-induced transactivation of PDGF-R
in HBEpCs.
Role of PLD2 Rather Than PLD1 in LPA-induced PDGF-R
Phosphorylation—To investigate further the involvement of
PLD isoenzymes in LPA-induced PDGF-R transactivation, we
overexpressed wild type and catalytically inactive mutants of
hPLD1 and mPLD2. HBEpCs (50% confluence) were infected
with the adenoviral constructs (50 pfu/cell) for 12, 24, and 48 h,
and cell lysates were analyzed for enhanced expression of
PLD1 and PLD2 proteins by Western blot analysis using N-
terminal plus internal anti-PLD1 or anti-PLD2 antibodies. As
shown in Fig. 10A, infection of HBEpCs with adenoviral con-
structs increased the expression of PLD1 and PLD2 proteins in
a time-dependent fashion with expression of the proteins seen
as early as 12 h and maximum expression observed at 48 h
after infection. The functional roles of hPLD1 and mPLD2
overexpression were tested by determining which of the isoen-
zymes of PLD are activated by LPA in HBEpCs. In both control
and vector-infected cells, 1 M LPA stimulated [32P]PBt forma-
tion by 4–5-fold compared with an increase of 7.5-fold in cells
that overexpressed hPLD1. Overexpression of mPLD2 in-
creased basal PLD activity by about 3.6-fold, and this activity
was increased further by about 5-fold by stimulation of cells
with LPA (Fig. 10B). By contrast, overexpression of catalyti-
cally inactive mutant of mPLD2 (K758R), but not hPLD1
(K898R), partially blocked LPA-mediated [32P]PBt accumula-
tion (Fig. 10B). These results show that LPA stimulates PLD2
PLD1, and the catalytically inactive mutant of mPLD2 atten-
uated LPA-mediated [32P]PBt formation in HBEpCs.
We then used these cells that expressed wild type and cata-
lytically inactive mutants of hPLD1 and mPLD2 to study their
respective roles in activation of the PDGF-R. As shown in Fig.
11A, overexpression of either wild type hPLD1 or its mutant
K898R had no effect on LPA-mediated PDGF-R phosphoryla-
tion. However, in cells infected with cDNA for wild type
mPLD2, the basal (1.5-fold change) as well as LPA-mediated
(3.0-fold change) phosphorylations of the PDGF-R were sig-
nificantly higher compared with the cells infected with empty
vector (Fig. 11B). Overexpression of the catalytically inactive
mutant of mPLD2 attenuated both the basal and LPA-induced
phosphorylation of PDGF-R (Fig. 11B). These results estab-
lish the involvement of PLD2, rather than PLD1, in LPA-
mediated PDGF-R transactivation in HBEpCs.
To study this action further, we investigated possible inter-
action among PLD1, PLD2, and PDGF-R in the absence or
presence of LPA. HBEpCs were infected with adenoviral con-
structs of wild type hPLD1, mPLD2, and catalytically inactive
mutants hPLD1 (K898R) and mPLD2 (K758R) for 12 h followed
by a second transfection with wild type PDGF-R for another
24 h. Immunoprecipitation of the PDGF-R from vehicle and
LPA-challenged cells resulted in coimmunoprecipitation of wild
type mPLD2 and catalytically inactive mutant mPLD2-K758R
expressed proteins compared with vector control (Fig. 12A).
Relative to mPLD2, the amount of hPLD1 that coimmunopre-
cipitated with PDGF-R was almost negligible in vehicle and
LPA-stimulated HBEpCs (Fig. 12A). The Western blots for
PLD1 and PLD2 in PDGF-R immunoprecipitates were carried
out simultaneously and for the same exposure times to ensure
identical development of the samples. In contrast to coimmu-
FIG. 4. Dose-dependent phosphorylation of PDGF-R by LPA.
HBEpCs (passage 3,  90% confluence) in 35-mm dishes were chal-
lenged with increasing concentrations of LPA as indicated for 5 min,
and cell lysates were analyzed by Western blotting with phospho-
specific PDGF-R (tyrosine 716) and PDGF-R antibodies as described
under “Experimental Procedures.” Values are the means  S.D. from
three independent experiments, and -fold increases in PDGF-R phos-
phorylation were normalized to total PDGF-R. The histogram is ex-
panded vertically.
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noprecipitation with PDGF-R, a comparable expression of
PLD1 and PLD2 proteins was observed in total cell lysates
from control and LPA-treated cells (Fig. 12B). Although stim-
ulation of cells with PDGF-BB increased tyrosine phosphoryl-
ation of PDGF-R, overexpression of either the wild type
mPLD2 or catalytically inactive PLD2 mutant had no effect on
PDGF-R phosphorylation (data not shown). Presumably,
PDGF did not increase association of PLD2 with PDGF-R.
These results show that in HBEpCs, PDGF-BB mediated phos-
phorylation of PDGF-R is independent of PLD stimulation in
HBEpCs, and PLD2, but not PLD1 forms a physical complex
with PDGF-R which is independent of the catalytic activity of
PLD2.
DISCUSSION
LPA mediates cellular responses through its GPCRs. Many
responses to LPA such as proliferation, anti-apoptotic, and
tumor invasiveness are mediated by signaling pathways of
protein kinase C, Src kinase, ERK, phospholipases, and Ca2
(40). Many GPCRs, including those for platelet-activating fac-
tor, S1P, LPA, thrombin, insulin-like growth factor I, chemo-
kine CXCR-1/2, 2-adrenergic agonists, and angiotensin II (28,
30, 31, 41–45) activate ERK1/2 involving transactivation of
receptor tyrosine kinases. Earlier studies showed that LPA
induces protein-tyrosine phosphorylation in fibroblasts and ex-
hibits growth factor-like properties via ERK activation (36).
The role of LPA and its receptors in bronchial epithelial cell
signal transduction and cellular responses has not been well
characterized. Here we report for the first time that LPA trans-
activates PDGF-R in HBEpCs, resulting in stimulation of
ERK1/2. Furthermore, we demonstrated a novel mechanism
that this transregulation of the PDGF-R by LPA is mediated by
coupling to Gi and PA generated by PLD2, but not PLD1.
LPA-1, LPA-2, and LPA-3 receptors are present in the lung
(46). RT-PCR studies have confirmed mRNA for all the three
receptors in isolated human aortic smooth muscle cells (47). In
HBEpCs, we detected the mRNA for all the three receptors by
RT-PCR, protein expression by Western blotting with LPA-R
specific antibodies, and immunocytochemistry (Fig. 1). Inter-
estingly, the immunocytochemical analysis revealed that the
LPA-Rs apparently have differential subcellular localizations.
LPA-Rs were detected not only on the plasma membrane, but
also in the cytoplasm, endoplasmic reticulum, and perinuclear
location. Western blot analysis using antibodies directed
against internal domains of LPA1–3 of the LPA1–3 receptors
revealed considerable specificity with LPA-2 antibody exhibit-
ing a single band corresponding to the expected weight of each
receptor (data not shown). The intracellular distribution of
LPA-Rs indicates that they may be targets of the LPA gener-
ated after agonist stimulation (48). More than one LPA-R could
be involved in LPA-induced ERK1/2 activation. Further studies
on the types of LPA-Rs that are coupled to different GPCRs and
native LPA-R localization will help in understanding intracel-
FIG. 5. LPA stimulates phosphorylation of PDGF-R. A, HBEpCs (passage 3, 80% confluence in 35-mm dishes) were transfected with
PDGF-R plasmid DNA for 4 h, then medium containing DNA-transfection reagent complex was replaced with conditioned BEBM, and cells were
cultured for another 24 h and challenged with 1 M LPA for various times as indicated. To cell lysates (1 mg of protein), 2 g/ml anti-PDGF-R
antibody was added, incubated for 18 h at 4 °C followed by the addition of 20 l of Sepharose A/G and additional incubation for 2 h at 4 °C. The
immunocomplex was centrifuged at 5,000  g for 10 min, and the pellet was washed three times with ice-cold RIPA buffer containing 1 mM
orthovanadate and protease inhibitors. The immunoprecipitates (IP) were subjected to SDS-PAGE, transferred onto polyvinylidene difluoride
membrane, and probed with anti-tyrosine antibody. Membranes were stripped and reprobed with anti-PDGF-R antibody for total PDGF-R. B,
cell lysates were also analyzed by Western blotting with phospho-specific anti-PDGF-R antibody (against tyrosine 716). Values are the means 
S.D. from three independent experiments, and -fold changes in PDGF-R phosphorylation were normalized to total PDGF-R. The histograms are
shrunk horizontally to fit under the blots.
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lular targets of LPA and its action.
LPA-Rs are coupled to heterotrimeric G proteins: Gi, Gq/G11,
and G12/13, increasing the complexity in signaling pathways
inducing multiple cellular responses. In HASMs, ERK activa-
tion by LPA was blocked by PTx treatment (1, 49). In fibro-
blasts, LPA-stimulated cell growth and decreased in cAMP was
sensitive to PTx, suggesting coupling of LPA-Rs to Gi (8). Sim-
ilarly, LPA-mediated activation of the Ras/mitogen-activated
protein kinase cascade and cell migration occurred in a PTx-
FIG. 6. AG 1296 attenuates LAP- and PDGF-BB mediated PDGF-R phosphorylation. HBEpCs (passage 2, 80% confluence) in 35-mm
dishes were treated with varying concentrations of tyrphostin AG 1296 (A) or 1 M AG 1296 (B) for 1 h. Subsequently the cells challenged with
1 M LPA as in A or 20 ng/ml PDGF-BB as in B for 5 min in BEBM with 0.1% BSA. Cell lysates were subjected to SDS-PAGE and Western blotting
with phospho-specific PDGF-R (tyrosine 716) and PDGF-R antibodies. Values are the means  S.D. of triplicate determinations, and -fold
increases in PDGF-R phosphorylation were normalized to total PDGF-R. *, p  0.05 compared with vehicle control; **, p  0.05 compared with
PDGF treatment.
FIG. 7. PTx blocks LPA-induced PDGF-R transactivation.
HBEpCs (passage 3, 90% confluence) in 35-mm dishes were treated
with 100 ng/ml PTx for 12 h prior to challenge with 1 M LPA for 15
min. Cell lysates were prepared and analyzed for PDGF-R phospho-
rylation with phospho-specific PDGF-R (tyrosine 716) and PDGF-R
antibodies. Values are the means  S.D. of three independent experi-
ments, and -fold changes in PDGF-R phosphorylation were normalized
to total PDGF-R. *, p  0.05 compared with vehicle control; **, p 
0.05 compared with LPA treatment.
FIG. 8. Detection of PLD1 and PLD2 in HBEpCs by RT-PCR
and Western blotting. A, total RNA was extracted from primary
HBEpCs, and transcription of the genes encoding PLD1 and PLD2 was
assessed by RT-PCR ( indicates in the absence of RNA, and  indi-
cates in the presence of 2 g of RNA) with primers as indicated under
“Experimental Procedures.” RT-PCR products were visualized by
ethidium bromide staining after separation on agarose gels. B, cell
lysates (40 g of protein) were subjected to SDS-PAGE on 6% gels and
analyzed by Western blotting with PLD1 (internal  N-terminal anti-
bodies, 1:500 dilution) and PLD2 (internal  N-terminal antibodies,
1:1,000 dilution). The Western blot is representative of three independ-
ent experiments.
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sensitive manner with the possible involvement of G sub-
units (10). However, in several mammalian cells, LPA-induced
stimulation of phospholipase C was PTx-insensitive, suggest-
ing LPA-R coupling to Gq (50). A role for the G12/13 family of
heterotrimeric G proteins in LPA-induced actin stress fiber and
focal adhesions has been described in quiescent Swiss 3T3
fibroblasts (13). Our present results demonstrate that LPA-
induced transactivation of PDGF-R and ERK1/2 stimulation
is PTx-sensitive, suggesting involvement of Gi protein-depend-
ent signaling responses in HBEpCs (Figs. 3 and 7). The LPA-
R-mediated ERK1/2 activation appears to be secondary to
transactivation and phosphorylation of PDGF-R because the
PDGF-R tyrosine kinase inhibitor AG 1296 (51, 52) partially
blocked LPA-induced ERK stimulation (Fig. 2). There are sev-
eral reports demonstrating transactivation of EGF-R by LPA
(31, 50, 53–57). Tyrphostin AG 1478, an inhibitor of EGF-R
kinase, blocked LPA-induced EGF-R phosphorylation, suggest-
ing transactivation of EGF-R by LPA in HBEpCs (results not
shown). Furthermore, pretreatment of HBEpCs with AG 1296
plus AG 1478 almost completely attenuated LPA-mediated
phosphorylation of ERK1/2 (results not shown) compared with
the partial block with AG 1296 alone (Fig. 2). These results
suggest that in HBEpCs, transactivation of both EGF-R and
PDGF-R by LPA plays a major role in the activation of ERK1/2.
Further studies are required to evaluate the mechanisms for
transactivation of the EGF receptor with respect to ERK
signaling.
LPA-R-induced EGF-R transactivation involves the matrix
metalloproteinase-dependent proteolytic processing of mem-
brane-anchored proligands of EGF-R (31). However, in our
experiments, LPA-induced transactivation of PDGF-R was not
attenuated by the nonspecific matrix metalloproteinase inhib-
itor GM 6001 in HBEpCs (results not shown). Furthermore,
inhibitors of protein kinase C such as bisindolylmalemide and
Gö 6738 failed to block LPA-induced PDGF-R phosphorylation,
suggesting that protein kinase C is not involved. LPA-induced
transactivation of PDGF-R was attenuated by butan-1-ol, but
not butan-3-ol in HBEpCs (Fig. 9), demonstrating a role for
TABLE I
Effect of AG 1296 on PLD activation by LPA, PDGF-BB, and
12-O-tetradecanoylphorbol-13-acetate (TPA) in HBEpCs
HBEpCs were labeled with 32Pi (20 Ci/ml) in BEBM serum-free
medium for 18 h. The radioactive medium was aspirated, and cells were
pretreated with AG 1296 (10 M) for 1 h prior to addition of either LPA
(1 M) or PDGF-BB (50 ng/ml) or 12-O-tetradecanoylphorbol-13-acetate
(TPA) (25 nM) for 15 min in the presence 0.1% BSA and 0.05% butan-
1-ol. Lipids were scraped under acidic conditions with methanol:HCl
and extracted with chloroform as described under “Experimental Pro-
cedures.” The formation of [32P]PBt, an index of PLD activation, was
quantified by scintillation counting after separation of the labeled lipids
by thin layer chromatography using 1% potassium oxalate plates de-
veloped with the upper phase of ethyl acetate:iso-octane:glacial acetic
acid:water (65:10:15:50, v/v). Values are the means  S.D. of three
independent experiments in triplicate. Counts (dpm) in [32P]PBt were




Vehicle Vehicle 550  71
Vehicle LPA (1 M) 3,081  382
Vehicle PDGF-BB (50 ng/ml) 682  21
Vehicle TPA (25 ng/ml) 3,708  234
AG 1296 (10 M) Vehicle 422  33
AG 1296 (10 M) LPA (1 M) 2,796  208
AG 1296 (10 M) PDGF-BB (50 ng/ml) 538  46
AG 1296 (10 M) TPA (25 ng/ml) 3,432  136
FIG. 9. Butan-1-ol, but not butan-3-ol, attenuates LPA-induced
PDGF-R phosphorylation. HBEpCs (passage 2, 80% confluence)
in 35-mm dishes were pretreated with BEBM or BEBM plus 0.1%
butan-1-ol or 0.1% butan-3-ol for 15 min and then challenged with 1 M
LPA in 0.1% BSA for an additional 15 min. Cell lysates (20–30 g of
protein) were subjected to SDS-PAGE and Western blotting with phos-
pho-specific PDGF-R (tyrosine 716) and PDGF-R antibodies. Values
are the means  S.D. from three independent experiments, and -fold
changes PDGF-R phosphorylation were normalized to total PDGF-R
in total cell lysates. *, p  0.05 compared with vehicle control; **, p 
0.05 compared with LPA treatment; ***, p  0.05 compared with LPA
treatment.
FIG. 10. Effects of overexpression of wild type and catalyti-
cally inactive mutants of hPLD1 and mPLD2 on LPA-induced
[32P]PBt formation. A, HBEpCs ( 50% confluence in 35-mm dishes)
were infected with empty vector or adenoviral vectors containing cDNA
for wild type hPLD1 or mPLD2 or mutant forms of hPLD1 or mPLD2
(50 pfu/cell; 1.5  105 cells/dish) in complete BEBM for 12, 24, and 48 h.
Cell lysates were prepared as described under “Experimental Proce-
dures” and subjected to SDS-PAGE and Western blotting with internal
plus N-terminal PLD1 and PLD2 antibodies. B, HBEpCs (50% con-
fluence in 35-mm dishes) were infected as described above for 24 h and
subsequently labeled with 32Pi for 18 h. Cells were challenged with
BEBM or BEBM plus 1 M LPA containing 0.1% BSA and 0.05%
butan-1-ol for 15 min. Lipids were extracted under acidic conditions,
and [32P]PBt formed was quantified after separation of the total lipid
extracts by thin layer chromatography. Values are the means  S.D. of
triplicate determinations from three independent experiments and nor-
malized to 106 dpm in total lipid extracts. *, p  0.05 compared with
vehicle control/vector; **, p  0.05 compared with LPA treatment in
vector-infected cells; ***, p  0.05 compared with LPA treatment in
vector-infected cells; ****, p  0.05 compared with vector-infected cells.
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PLD in transactivation of PDGF-R. Using formation of
[32P]PBt in the presence of butan-1-ol as an index of PLD
activation, we demonstrated that LPA but not PDGF-BB acti-
vated PLD in HBEpCs (Table I). Additionally, infecting cells
with adenoviral constructs of wild type hPLD1 and mPLD2
demonstrated that LPA rapidly and transiently activated both
PLD1 and PLD2 in HBEpCs.
Earlier, we showed that S1P activated both PLD1 and PLD2
in Beas-2B bronchial epithelial cells (21). In the present work,
the participation PLD2, but not PLD1, in LPA-mediated trans-
activation of PDGF-R was established by the demonstration
that overexpression of mPLD2-K758R, but not the hPLD1-
K898R mutant, blocked LPA-induced phosphorylation of
PDGF-R. The two PLD mutants had no effect on PDGF-BB-
induced phosphorylation of PDGF-R, confirming that PLD was
not activated downstream of PDGF binding to PDGF-R in
HBEpCs. These results provide the first direct evidence for
activation of both PLD1 and PLD2 in HBEpCs and for the
participation of PLD2 but not PLD1 in LPA-induced transac-
tivation of PDGF-R. Our results (Fig. 12A) show that wild type
and catalytically inactive mutant of mPLD2 coimmunoprecipi-
tated with PDGF-R to a greater extent compared with PLD1
before and after stimulation of HBEpCs with LPA. Also, mu-
tation of mPLD2 at a single amino acid residue at 758 from Lys
to Arg had no appreciable effect on its interaction with the
PDGF-R (Fig. 12A). However, this mutation at the catalytic
site of mPLD2 almost completely reversed LPA-induced trans-
activation of PDGF-R. Earlier studies using human embry-
onic kidney fibroblasts transfected with wild type PLD1 or
PLD2 demonstrated that EGF stimulated PLD1 activity to a
greater extent than PLD2, but only PLD2 was associated with
EGF-R (58). Furthermore, PLD2 was tyrosine phosphorylated
upon EGF-R activation by EGF (59). However, in HBEpCs,
PLD was not activated by PDGF (Table I) or EGF (results not
shown), and it is unclear whether LPA enhanced tyrosine phos-
phorylation of PLD2. Studies with rat 3Y1 fibroblasts, overex-
pressing the EGF-R established a role for both PLD1 and PLD2
in EGF-induced receptor degradation suggesting that PLD sig-
naling is involved in receptor endocytosis (60).
Our work, therefore, established a novel mechanism by
which PLD2 participates in the transactivation of PDGF-R.
We have not yet elucidated the mechanisms for activation other
than to establish that PLD2 interacts physically with
PDGF-R and that the formation of PA is required. We have
also not investigated the details of how PLD2 is activated by
exogenous LPA, but this involves a receptor, probably LPA-1,
that is coupled to Gi. Src kinase plays a central role in GPCR
signaling by transactivating the EGF-R or vascular EGF-R
(Flk-1/KDR) (61). For example, adrenergic receptor-mediated
EGF-R phosphorylation and S1P-induced Flk-1/KDR transac-
tivation (32, 62) were sensitive to Src kinase inhibitors PP1/
PP2 (63). Our work with endothelial cells established that Src
can be upstream of activation of PLD1 and PLD2 by diperox-
ovanadate (64). Therefore, such an LPA-induced activation of
Src in HBEpCs could mediate the PLD2-induced activation of
PDGF-R. It is also significant that the PDGF-R can be teth-
ered to GPCRs, including S1P-1, thus providing an integrative
signaling pathway (33). Our present results suggest that PLD2
could be a component of such a complex.
In summary, we demonstrate for the first time that LPA
mediates transactivation of PDGF-R in HBEpCs through PLD
and PA production. Although LPA activates both PLD1 and
PLD2, PLD2, but not PLD1, regulates PDGF-R phosphoryla-
tion and activation. Also, LPA increases PLD2 association with
FIG. 11. Effects of overexpression of wild type and mutants of hPLD1 and mPLD2 on LPA-induced PDGF-R phosphorylation. A,
HBEpCs (50% confluence in 35-mm dishes) were infected with adenoviral vectors containing cDNA for wild type hPLD1 or mutant hPLD1 (50
pfu/cell, 1.5  105 cells) for 48 h. Cells were challenged with BEBM or BEBM plus 1 M LPA containing 0.1% BSA for 5 min. B, HBEpCs were
infected with vector or wild type mPLD2 or mutant mPLD2 for 48 h before challenging with 1 M LPA for 5 min as described above. Cell lysates
were subjected to SDS-PAGE and Western blotting (IB) with phospho-specific PDGF-R (tyrosine 716) and PDGF-R antibodies. Values are the
means  S.D. of three independent experiments in triplicate. -Fold increases in PDGF-R phosphorylation were normalized to total PDGF-R in
the cell lysates.
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PDGF-R. Our results, therefore, demonstrate that PLD2 is
activated upstream from PDGF-R activation. PDGF signaling
is involved in cell proliferation and tumorigenesis as well as
lung development. Our work establishes that LPA through
stimulating PLD2 activity plays an important role in activating
the PDGF-R and therefore ERK. LPA-induced transactivation
of the PDGF-R could, therefore, be involved in modulating
airway remodeling and lung function.
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FIG. 12. Effects of overexpression of wild type and mutant
mPLD2 on coimmunoprecipitation of PDGF-R with PLD2 after
LPA treatment. A, HBEpCs (passage 3, 50% confluence in 35-mm
dishes) were infected with adenoviral vectors containing cDNA for wild
type or mutant mPLD2 (50 pfu/cell, 1.5  105 cells) for 24 h. Cells were
then transfected with wild type PDGF-R plasmid with FuGENE 6 for
5 h. Then the medium was replaced with fresh BEBM and cells cultured
for an additional 24 h. Cells were challenged with BEBM or BEBM plus
1 M LPA in 0.1% BSA for 5 min. Cell lysates (1 mg of protein/ml) were
subjected to immunoprecipitation (IP) under nondenaturing conditions
with PDGF-R antibody for 18 h in the presence of Sepharose A/G (20
l/mg protein). The PDGF-R immunoprecipitates were subjected to
SDS-PAGE and Western blotting (IB) with PDGF-R and internal plus
N-terminal PLD2 antibodies. B, cell lysates (20 g of protein) were
subjected to SDS-PAGE and Western blotting with internal plus N-
terminal PLD2 antibody.
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